Evotec Stock Price, News & Analysis (OTCMKTS:EVTCY) $9.99 +0.17 (+1.73%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$9.90▼$10.1650-Day Range$8.33▼$10.5352-Week Range$14.22▼$26.57Volume31,526 shsAverage Volume2,407 shsMarket Capitalization$3.30 billionP/E Ratio24.37Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings About Evotec Stock (OTCMKTS:EVTCY)Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Read More EVTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVTCY Stock News HeadlinesNovember 12, 2023 | finance.yahoo.comEvotec SE (NASDAQ:EVO) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comEQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate updateDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 5, 2023 | finance.yahoo.com65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in SingaporeSeptember 27, 2023 | finance.yahoo.comEvotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D EconomySeptember 21, 2023 | finance.yahoo.comEvotec SE (EVO) Stock Historical Prices & Data - Yahoo FinanceMay 30, 2023 | finance.yahoo.comIs There Now An Opportunity In Evotec SE (ETR:EVT)?May 14, 2023 | finance.yahoo.comEvotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value EstimateDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 13, 2023 | finanznachrichten.deEvotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023May 12, 2023 | investing.comEvotec SE ADR (EVO) Earnings Dates & ReportsMay 10, 2023 | investing.comEvotec SE ADR (EVO)May 9, 2023 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial ManufacturingApril 10, 2023 | finance.yahoo.comEvotec SE Provides Update on Cyber AttackFebruary 10, 2023 | finanznachrichten.deEvotec SE: Evotec Receives € 150 m Loan from European Investment BankJanuary 31, 2023 | markets.businessinsider.comEQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionDecember 22, 2022 | ca.finance.yahoo.comWith 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investorsDecember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers SquibbSeptember 21, 2022 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies ProgramSeptember 20, 2022 | markets.businessinsider.comEvotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of DefenseSeptember 17, 2022 | finanznachrichten.deEvotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, FranceAugust 13, 2022 | seekingalpha.comEvotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | nasdaq.comEvotec Slips To Loss In Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA ForecastAugust 11, 2022 | markets.businessinsider.comDGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updatesAugust 11, 2022 | finance.yahoo.comEvotec SE Reports Results for the First Half-year 2022 and Provides Corporate UpdatesAugust 10, 2022 | finanznachrichten.deEvotec SE: Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303May 11, 2022 | nasdaq.comEvotec Q1 Adj. EBITDA Down, Revenues UpSee More Headlines Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EVTCY CUSIPN/A CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees3,572Year Founded1993Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio23.95 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales5.67 Cash Flow$0.09 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book3.90Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$3.24 billion OptionableNot Optionable Beta0.98 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesWerner LanthalerChief Executive OfficerCraig L. JohnstoneChief Operating Officer & Member-Management BoardEnno SpillnerChief Financial OfficerCord E. DohrmannChief Scientific OfficerVolker BraunSVP, Head-Investor Relations & ESGKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMAmicus TherapeuticsNASDAQ:FOLDCytokineticsNASDAQ:CYTKHUTCHMEDNASDAQ:HCMUltragenyx PharmaceuticalNASDAQ:RAREView All Competitors EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed in 2023? Evotec's stock was trading at $8.09 at the beginning of 2023. Since then, EVTCY shares have increased by 23.5% and is now trading at $9.99. View the best growth stocks for 2023 here. When did Evotec's stock split? Evotec shares split on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were payable to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Evotec have any subsidiaries? The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.Read More This page (OTCMKTS:EVTCY) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.